LivaNova PLC (LIVN)

NEUTRAL

HealthcareMedical DevicesUnited Kingdom

Fundamental

मूल्य

$79.49

मार्केट कैप

$4.31B

Yahoo Finance TradingView समाचार वेबसाइट

भाग 1 · कंपनी का मूल्य कितना है

अवलोकन

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

बैलेंस शीट और तरलता

राजस्व

$1.47B

पिछले 12 महीने (30/6/2026 तक)

शुद्ध आय

$189M

पिछले 12 महीने (30/6/2026 तक)

Free Cash Flow

$173M

कुल इक्विटी

$1.20B

कुल देनदारियाँ

$1.41B

Current Ratio

1.45

Interest Coverage

5.43

Debt/EBITDA

1.30

Earnings Per Share

राजस्व और शुद्ध आय

Free Cash Flow

आय विवरण

ऐतिहासिक विवरण

समय के साथ मार्जिन

समय के साथ ऋण

ऋण कितना भारी है

वृद्धि तालिका

वृद्धि — राजस्व

Fair Value अनुमान

General caseउचित मूल्यांकित

Fair Value

$68.03

वर्तमान मूल्य

$79.49

Margin of Safety

-16.8%

Fair Value सीमा

$50.54 - $85.52

अनुमान विधियाँ

Analyst price target:$88.80

Discounted cash flow (DCF):$64.43

Earnings multiple (P/E):$61.63

Graham growth formula:$55.19

Earnings power value (EPV):$27.82

Justified P/B:$41.65

Dividend discount (Gordon):Not enough data to compute it

P/FFO, funds from operations:Not enough data to compute it

Mid-cycle earnings:$9.76

Revenue multiple:Not enough data to compute it

विश्लेषक सहमति:दृढ़ खरीदें (13B / 3H / 0S)

अंतिम Earnings सरप्राइज़:+12.32%

मूल्यांकन मेट्रिक्स

P/E Ratio

23.09

ROE

-20.2%

P/B Ratio

3.25

P/FCF

29.07

Gross Margin

68.1%

ROIC

7.7%

लाभप्रदता Radar

Value Creation (Economic Moat)

ROIC

7.7%

WACC

9.4%

ROIC − WACC

-1.8 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental विश्लेषण मानदंड

पास (18)

Price CAGR 5.76%
ROIC 7.7%
Gross Margin 68.1%
P/FCF 29.07
Debt/Equity ratio
Operating Margin 12.7%
Positive Free Cash Flow
Current Ratio
Interest Coverage
Debt/EBITDA
Return on Tangible Assets
ROE 15.4%
Revenue Growth 5Y 8.2%
Analyst Consensus 81% Buy
Earnings Surprise avg 10.3%
Earnings Quality (OCF/NI) 1.32
Share Dilution -0.0%
Net Margin Trend 12.8% vs -16.1%

फेल (7)

EPS shows upward trend
P/B Ratio 3.25
CapEx intensity
Low reliance on intangibles
Price below Graham Number
DCF valuation (Overvalued)
Piotroski F-Score 4/9

अनुपलब्ध (2)

Dividend Payout NaN%
PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

4/9

मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक

score

criteria

Earnings गुणवत्ता

1.32

उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित

शेयर Dilution

0.0%

शेयर वापस खरीद रही है। शेयरधारक अनुकूल

प्रशासन

कार्यकारी टीम

नाम	पद	आयु
Mr. Vladimir A. Makatsaria	CEO & Director	52
Mr. Alex Shvartsburg C.M.A.	Chief Financial Officer	55
Ms. Natalia Sergeyevna Kozmina	Chief Human Resources Officer	54
Mr. Ahmet Tezel Ph.D.	Chief Innovation Officer	50
Ms. Lindsey Little	VP & Chief Accounting Officer	-
Briana Gotlin	Vice President of Investor Relations	-
Ms. Sarah K. Mohr	VP of Legal & Company Secretary	-
Deanna Wilke	Vice President of Corporate Communications	-
Mr. Philip Kowalczyk	Chief Strategy & Corporate Development Officer	-
Mr. Paul R. Buckman	President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement	69

Audit जोखिम

बोर्ड जोखिम

मुआवजा जोखिम

शेयरधारक अधिकार जोखिम

भाग 2 · कीमत और खरीदने का समय

यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।

Latest News

Recent headlines for LIVN, sourced from Markets Gazette.

2/25/2026NEUTRAL
LivaNova (LIVN) Q4 2025 Earnings Call Transcript
The transcript of LivaNova PLC's Q4 2025 earnings conference call is now available, providing investors with a critical opportunity to delve into the company's financial performance and future outlook. While the specific content has not been disclosed, analysts and shareholders will be scrutinizing management's statements regarding revenues, profit margins, product pipeline, and guidance for the current fiscal year. This data is essential for assessing LivaNova's operational health and anticipating potential stock movements, thereby influencing both short-term and long-term investment strategies.

via Markets Gazette